GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Days Payable

BCRX (BioCryst Pharmaceuticals) Days Payable : 300.60 (As of Sep. 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Days Payable?

BioCryst Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2024 was $10.6 Mil. BioCryst Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2024 was $3.2 Mil. Hence, BioCryst Pharmaceuticals's Days Payable for the three months ended in Sep. 2024 was 300.60.

The historical rank and industry rank for BioCryst Pharmaceuticals's Days Payable or its related term are showing as below:

BCRX' s Days Payable Range Over the Past 10 Years
Min: 590.49   Med: 1169.44   Max: 10505.72
Current: 590.49

During the past 13 years, BioCryst Pharmaceuticals's highest Days Payable was 10505.72. The lowest was 590.49. And the median was 1169.44.

BCRX's Days Payable is ranked better than
79.69% of 714 companies
in the Biotechnology industry
Industry Median: 127.37 vs BCRX: 590.49

BioCryst Pharmaceuticals's Days Payable declined from Sep. 2023 (982.22) to Sep. 2024 (300.60). It may suggest that BioCryst Pharmaceuticals accelerated paying its suppliers.


BioCryst Pharmaceuticals Days Payable Historical Data

The historical data trend for BioCryst Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Days Payable Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 968.22 3,560.82 1,168.79 1,166.96 1,380.16

BioCryst Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 982.22 876.82 1,075.17 518.24 300.60

Competitive Comparison of BioCryst Pharmaceuticals's Days Payable

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Days Payable falls into.



BioCryst Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

BioCryst Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (14.356 + 20.893) / 2 ) / 4.661*365
=17.6245 / 4.661*365
=1,380.16

BioCryst Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

Days Payable (Q: Sep. 2024 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2024 ) + Accounts Payable (Q: Sep. 2024 )) / count ) / Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=( (7.786 + 13.482) / 2 ) / 3.228*365 / 4
=10.634 / 3.228*365 / 4
=300.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie director 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin director ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244